Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 3 Study of CS-8958 (Prophylaxis for children)
jRCT2080222627Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing laninamivir 20 mg with placebo (2 arms). Primary endpoint: Efficacy for prevention of influenza virus infection. Started Oct 2014; status: completed.
02
Drugs
laninamivir
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2080222627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222627.